Last, quickly, my understanding of TRIPS, from all the testimony we've heard, is that regardless of whether or not a TRIPS waiver occurs, the actual ability to make a vaccine is a lot more complicated than just releasing patents and allowing these countries to make it. It requires a lot of ingredients, facilities and faculties.
Is it your understanding when you speak to your counterparts that making the vaccine more available to low-income or third world countries that need it, through agreements like the ones we've had before, is a better source of our attention rather than pondering only this as time flies by? Even if it were to be done, to actually organize and build capacity would be difficult for some of those marginalized countries.